Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/001389external-prioritypatent/WO2000009130A2/en
Application filed by Pfizer Products Inc.filedCriticalPfizer Products Inc.
Publication of BG105322ApublicationCriticalpatent/BG105322A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
The present invention relates to a new pharmaceutical use for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (N-NOS) inhibitors: (a) alone or in combination with another active agent for the treatment of psoriasis; (b) in combination with an anti-inflammatory agent for the treatment of inflammatory disorders; (c) in combination with a narcotic analgesic (e. g., opiates such as morphine or demerol) for the treatment of pain; (d) alone or in combination with other active agents for the enhancement of cognition; and (e) alone or in combination with other active agents for the treatment of sleep disorders such as apnea, narcolepsy and insomnia. 10 claims
BG105322A1998-08-112001-03-09New pharmaceutical use for nos inhibitors
BG105322A
(en)
Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them